30
Can
2022
The world’s leading cancer researchers will gather in Chicago from June 3 to 7 for the annual ASCO meeting - the first to be held in person since the Covid-19 pandemic. We are looking ahead to some of the most important details of the ICR research that will be presented at this year’s meeting.
Published May 30, 2022
by Gege Lee
Starting Friday, researchers at the Cancer Research Institute in London will be part of a global crowd of scientists and clinicians who will attend and present at the annual meeting of the American Clinical Oncology Society (ASCO) in Chicago.
ASCO is perhaps the biggest event in the oncology calendar, and this year’s conference is being held in person again after two years of virtual events, which is a welcome indicator that the world is returning to normal after Covid-19. The conference will also be available online, with access to the entire program through livestream and on-demand sessions.
The topic of this year’s meeting is Improving fair cancer care through innovationfocusing on the latest research and discoveries in cancer care that will help improve patients’ lives and contribute to a fairer future - whether it’s new innovations or smarter use of existing treatments.
We will highlight some of the studies presented by researchers at ICR and The Royal Marsden NHS Foundation Trust ahead of ASCO 2022 - as well as publish some exciting research from the conference. Check out our ASCO 2022 landing page for more information and updates.
Here are some ASCO summaries with our researchers:
Poster session
- Abstract 1019, on biomarkers in the studied PEARL cohort comparing palbocyclib and fulvestrant with capecitabine, was presented by Dr. Javier Pasqual
- Abstract 5041, on the reduction of alkaline phosphatase and survival in patients with metastatic castration-resistant prostate cancer treated with radium-223, was presented by Professor Nick James
- Abstract 8512, on pembrolizumab versus placebo for fully resected early-stage non-small cell lung cancer, presented by Professor Mary O’Brien
- Abstract TPS2691, on the study of phase I CBL-B inhibitors in patients with advanced malignant solid tumors, presented by Dr. Adam Sharp
- Abstract TPS2704, in a phase I study on a virus that expresses antibodies as a single agent and in combination with nivolumab in patients with advanced solid tumors, was presented by Professor Kevin Harrington
- Abstract TPS2705, in a phase I RP3 virus study as a single agent and in combination with nivolumab in patients with solid tumors, was presented by Professor Kevin Harrington
- Abstract TPS9158, on a study on the safety and efficacy of inupadenant in combination with chemotherapy for metastatic non-small lung cancer, presented by Professor Mary O’Brien
- Abstract TPS9159, in a phase III study of pralsetinib for advanced or metastatic non-small cell lung cancer cells, presented by Professor Sanjai Popat
Sessions and panels
In addition, ICR researchers will chair or speak at the following sessions and panels:
- Education on the combination of immunotherapy and radiotherapy for the treatment of head and neck cancer, chaired by Professor Kevin Harrington
- Education on best approaches and updates for prostate cancer recurrence, with speaker Professor Chris Parker
- Abstract 1009, on mutations and acquired resistance to fulvestrant in the plasma MATCH study, presented by Dr. Belinda Kingston
- Symposium on Biomarkers Outside Histology in Sarcoma Clinical Trials, with Discussant Dr. Paul Huang
- Symposium on the usefulness of genomics for directing the treatment of patients with breast cancer, with the discussant Professor Nick Turner
- Panel on long-term survival data for immune checkpoint inhibitors, with speaker Dr. Samra Turajlić
Join the conversation on social networks with the hashtag # ASCO2022!
Read more news and stories from the ASCO Annual Meeting.
ASCO Annual Meeting
Tags
ASCOASCO 2022
comments povered bi